SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000921895-23-001356
Filing Date
2023-05-25
Accepted
2023-05-25 15:49:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO THE SCHEDULE 13D sc13da513224004_05252023.htm SC 13D/A 306110
2 JOINDER AGREEMENT, DATED MAY 25, 2023 ex991to13da513224004_052523.htm EX-99.1 21574
  Complete submission text file 0000921895-23-001356.txt   329323
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89959 | Film No.: 23960248
SIC: 2834 Pharmaceutical Preparations

Mailing Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022
Business Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022 914-629-8496
Camac Fund, LP (Filed by) CIK: 0001516478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A